Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00473928 · ClinicalTrials.gov registry record · Phase 1
Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)
A Phase 1 study of Age-related Macular Degeneration, sponsored by Potentia Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
- 6
- Study locations
NCT00473928 is a Phase 1 study of Age-related Macular Degeneration that has completed, run by Potentia Pharmaceuticals. The registered enrollment target is 27 participants, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT00473928, a Phase 1 study of Age-related Macular Degeneration, has completed, sponsored by Potentia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD
Conditions Studied
Interventions
- DRUG POT-4
Study Locations (6)
Florida
- United States, Florida - Gainesville
- United States, Florida - Miami
Arizona
- United States, Arizona - Tucson
California
- United States, California - Beverly Hills
Minnesota
- United States, Minnesota - Rochester
New Hampshire
- United States, New Hampshire - Portsmouth
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00473928
The ClinicalTrials.gov registry entry for NCT00473928 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,507-participant average among 74 other Age-related Macular Degeneration trials with a reported enrollment target (98% lower). The listed sponsor is Potentia Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Age-related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which POT-4 is the first listed.
NCT00473928 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT00473928 about?
NCT00473928 is a clinical study titled "Safety of Intravitreal POT-4 Therapy for Patients With Neovascular Age-Related Macular Degeneration (AMD)". The objective of this study is to provide initial safety and tolerability information of intravitreal POT-4 for treatment of patients with AMD
What is the current status of trial NCT00473928?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2007-05. Estimated completion is 2010-02.
What conditions does trial NCT00473928 study?
This clinical trial studies the following conditions: Age-related Macular Degeneration.
What interventions are being tested in trial NCT00473928?
The interventions under investigation include: POT-4 (DRUG).
Who is sponsoring clinical trial NCT00473928?
This trial is sponsored by Potentia Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00473928 being conducted?
This trial has 6 study locations across Arizona, California, Florida, Minnesota, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 1
-
Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
RECRUITING · Phase 1
-
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
RECRUITING · Phase 1
-
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
RECRUITING · Phase 1
-
Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.